Across TCGA pan-cancer cohorts, AKR1D1 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated AKR1D1 data layer compared with 22 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AKR1D1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AKR1D1 expression acts as an unfavorable survival marker.
HNSC are the cancer types where AKR1D1 mass-spec protein most reproducibly stratifies survival.